Qritive, a pioneering healthcare AI company, has announced a strategic partnership with three prominent diagnostic centers and hospitals in India: Metropolis Healthcare, Rajiv Gandhi Cancer Institute, and CŌRE Diagnostics. These esteemed institutions have embraced Qritive's AI products alongside the Pantheon Image Management System (IMS) to bolster their diagnostic capabilities.By harnessing the power of artificial intelligence, these institutions aim to elevate diagnostic accuracy, streamline operational efficiency, and ultimately enhance patient care. Surendran Chemmenkottil, CEO of Metropolis Healthcare, expressed enthusiasm about the partnership, highlighting its potential to advance pathology standards, particularly in prostate cancer detection.

Bruno Occhipinti, CEO of Qritive, emphasized the role of deep tech in supporting clinicians and addressing the evolving needs of cancer care, in line with World Cancer Day's objectives on February 4th. Additionally, Mr. Dinesh Chauhan, CEO of CŌRE Diagnostics, underscored the integration of Qritive's AI solutions into their pathology workflow, foreseeing improved patient outcomes and the development of new AI services for rare disease diagnosis.

Clinical studies conducted at prestigious healthcare institutions have demonstrated significant reductions in diagnosis time and pathologist discordance, leading to heightened diagnostic accuracy and overall improvements in cancer patient care. Dr. Gurudutt Gupta, HOD Pathology at Rajiv Gandhi Cancer Institute Research Centre, praised the integration of AI tools for enhancing workflow efficiency and diagnostic precision, thereby offering substantial benefits to their practice.